FILE PHOTO: Brad Zakes (L), founder of Ethan Zakes Foundation/CEO of Cerevast Medical, and Nick Leschly, CEO of bluebird bio at the opening of Swiss pharmaceutical group Lonza’s dedicated cell and gene therapy facility in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer/File Photo